Anondita Medicare IPO is a book-built issue, aiming to raise ₹69.50 crore through a fresh issue of 47.93 lakh equity shares. The IPO opened for bidding on August 22, 2025, and closed on August 26, 2025, with allotment scheduled to be finalised on August 28, 2025. The company is set to list its equity shares on NSE SME, with the tentative listing date fixed as September 1, 2025.
The issue was priced in the range of ₹137 to ₹145 per share with a lot size of 1,000 shares. Investors were required to apply for a minimum of two lots, translating to 2,000 shares and an investment of ₹2,74,000. The IPO attracted significant investor interest, with an overall subscription of 300.89 times. Non-Institutional Investors (NIIs) led the response at 531.82 times, followed by retail investors at 286.20 times.
Anondita Medicare’s ₹69.50 crore IPO, priced at ₹137–₹145 per share, was subscribed 300.89 times in total. The public issue consisted entirely of a fresh issue of 47.93 lakh equity shares. Bidding took place from August 22 to August 26, 2025, with the allotment to be finalised on August 28, 2025. Listing is expected on September 1, 2025, on NSE SME. Retail investors subscribed 286.20 times, while NIIs subscribed 531.82 times their reserved quota.
The table below breaks down the Anondita Medicare share allocation for different categories, highlighting the number of shares and their percentage of the total issue. However, the key focus remains on the quotas allocated to retail investors and HNIs, as they are the most relevant for individual investors.
| Investor Category | Shares Offered |
| Market Maker Shares Offered | 2,70,000 (5.63%) |
| QIB Shares Offered | 22,56,000 (47.07%) |
| − Anchor Investor Shares Offered | 13,50,000 (28.17%) |
| − QIB (Ex. Anchor) Shares Offered | 9,06,000 (18.90%) |
| NII (HNI) Shares Offered | 6,81,000 (14.21%) |
| − bNII > ₹10L | 4,54,000 (9.47%) |
| − sNII < ₹10L | 2,27,000 (4.74%) |
| Retail Shares Offered | 15,86,000 (33.09%) |
| Total Shares Offered | 47,93,000 (100.00%) |
Data Source: NSE
| Category | Subscription (times) |
| Qualified Institutional Buyers | 153.03 |
| Non-Institutional Investors | 531.82 |
| Retail Individual Investors | 286.2 |
| Total | 300.89 |
Note: The subscription details are as of August 26, 2025
Anondita Medicare Limited was incorporated in March 2024, transitioning from a proprietorship concern into a public limited company. The company has positioned itself in the healthcare segment with a focus on contraceptive products, led by its flagship male condom brand “COBRA.” Its operations are supported by a dedicated manufacturing facility located in Noida, Uttar Pradesh, with an annual production capacity of around 562 million condoms.
The company has expanded its reach beyond the domestic market by exporting to regions such as Southeast Asia, Africa, and the Middle East. In addition, Anondita Medicare collaborates with global health organisations, non-governmental bodies, and governments to support family planning and public health initiatives. These strategic associations strengthen its credibility as a consistent supplier of quality healthcare products to both institutional and commercial clients.
Within India, Anondita Medicare benefits from a multi-channel distribution framework comprising wholesalers, retailers, and e-commerce platforms, which helps maintain strong accessibility for its products. The company also supplies directly to government health programmes and institutions, which adds scale and stability to its operations. This dual focus on domestic and international markets has contributed to its rapid growth in a short span of time.
As of July 31, 2025, the company employed 280 staff members. Its competitive strengths lie in being one of the more established condom manufacturers in India, particularly recognised in North India, alongside a diverse product portfolio. Backed by consistent growth in financial performance, expanding exports, and industry linkages, Anondita Medicare is emerging as a notable player in the contraceptive and healthcare product space.
Know more about IPO allotment status and check your application details online for the latest updates on share allocation.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Aug 26, 2025, 6:47 PM IST
Akshay Shivalkar
Akshay Shivalkar is a financial content specialist who strategises and creates SEO-optimised content on the stock market, mutual funds, and other investment products. With experience in fintech and mutual funds, he simplifies complex financial concepts to help investors make informed decisions through his writing.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
